Emeryville, CA
Zogenix, Inc. operates as a specialty pharmaceutical company with proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. The Company offers product candidates include a product that enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine.
zogenix.comThese are collections Zogenix is a part of. Click on the collection name to view similar companies.
Post Ipo Debt
$230,000,000
Post Ipo Equity
$230,253,000
Post Ipo Equity
$312,000,000
Post Ipo Equity
$288,937,500
Post Ipo Equity
$69,000,000
Post Ipo Equity
$98,325,000
Post Ipo Equity
$60,000,000
Post Ipo Debt
$30,000,000
Series Unknown
$15,000,000
Debt Financing
$35,000,000
IPO
Unknown
Series B
$35,004,188
Series B
$35,957,968
Debt Financing
$3,100,000
Series B
$18,000,000
Series A
$60,000,000
0 out of 5 stars
Based on 0 reviews
Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Zogenix.